A SATO ET AL: "S/GSK1349572 is a potent next-generation HIV integrase inhibitor", HIV MEDICINE, vol. 10, no. Suppl. 2, 19 October 2009 (2009-10-19), GB, pages 92 - 92, XP055582260, ISSN: 1464-2662, DOI: 10.1111/j.1468-1293.2009.00792.x (B1)

ANONYMOUS: "A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects - Full Text View - ClinicalTrials.gov", NCT00951015, 3 August 2009 (2009-08-03), XP055582403, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT00951015> [retrieved on 20190418] (B1)

BEALE K K ET AL: "COMBINATIONS OF REVERSE TRANSCRIPTASE, PROTEASE, AND INTEGRASE INHIBITORS CAN BE SYNERGISTIC IN VITRO AGAINST DRUG-SENSITIVE AND RT INHIBITOR-RESISTANT MOLECULAR CLONES OF HIV-1", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 46, no. 3, 1 June 2000 (2000-06-01), pages 223 - 232, XP001027294, ISSN: 0166-3542, DOI: 10.1016/S0166-3542(00)00083-8 (B1)

CAHN PEDRO ET AL: "Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials", THE LANCET, vol. 393, 9 November 2018 (2018-11-09), pages 143 - 155, XP093056157, DOI: dx.doi.org/10.1016/ S0140-6736(18)32462-0 (B1)

VAN WYK JEAN ET AL: "Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study", CLINICAL INFECTIOUS DISEASES, vol. 71, no. 8, 6 January 2020 (2020-01-06), US, pages 1920 - 1929, XP093056160, ISSN: 1058-4838, DOI: 10.1093/cid/ciz1243 (B1)

GALIZZI NADIA ET AL: "Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, ELSEVIER, AMSTERDAM, NL, vol. 55, no. 3, 9 January 2020 (2020-01-09), XP086083636, ISSN: 0924-8579, [retrieved on 20200109], DOI: 10.1016/J.IJANTIMICAG.2020.105893 (B1)

J ROCKSTROH ET AL: "Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)", JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 13, 8 November 2010 (2010-11-08), London, UK, pages O50 - O50, XP055582245, ISSN: 1758-2652, DOI: 10.1186/1758-2652-13-S4-O50 (B1)

J. LALEZARI ET AL: "Shionogi-GlaxoSmithKline Pharmaceuticals, LLC Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Na?ve HIV-1-Infected Patients: ING111521 Protocol", 5IAS 2009 - 5TH CONFERENCE ON HIV PATHOGENESIS, TREATMENT AND PREVENTION, 19 July 2009 (2009-07-19), Cape Town South Africa, pages 1 - 15, XP055280561 (B1)

LASKEY SARAH B. ET AL: "Quantitative evaluation of the antiretroviral efficacy of dolutegravir", JCI INSIGHT, vol. 1, no. 19, 17 November 2016 (2016-11-17), XP093056166, DOI: 10.1172/jci.insight.90033 (B1)

DATABASE Chemical Abstracts Regist [online] Chemical Abstracts Service; 22 September 2008 (2008-09-22), ANON.: "Dolutegravir", Database accession no. 1051375-16-6 (B1)